Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa

The ability of combinations of azlocillin and tobramycin to prevent or delay resistance development in eight Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients was studied using chequerboard titration and in-vitro serial subculture. No isolate had developed resistance to tobramycin a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of antimicrobial chemotherapy Ročník 44; číslo 3; s. 389
Hlavní autoři: Wu, Y L, Scott, E M, Po, A L, Tariq, V N
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 01.09.1999
Témata:
Anti-Bacterial Agents - pharmacology
Azlocillin - pharmacology
Cystic Fibrosis - microbiology
Drug Resistance, Microbial - physiology
Drug Therapy, Combination - pharmacology
Humans
Microbial Sensitivity Tests
Penicillins - pharmacology
Pseudomonas aeruginosa - drug effects
Pseudomonas aeruginosa - physiology
Pseudomonas Infections - microbiology
Tobramycin - pharmacology
ISSN:0305-7453
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The ability of combinations of azlocillin and tobramycin to prevent or delay resistance development in eight Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients was studied using chequerboard titration and in-vitro serial subculture. No isolate had developed resistance to tobramycin after 12 treatments with the antibiotic combination. Azlocillin resistance had not developed in four isolates after 16 exposures, and was delayed in the other four isolates for at least eight exposures. Beta-lactamase production was responsible for azlocillin resistance in two isolates and occurred to a lesser extent in a third.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0305-7453
DOI:10.1093/jac/44.3.389